URB937 (1 mg/kg, i.p.) administrated in mice increases anandamide levels in peripheral tissues, but not forebrain or hypothalamus[1].
URB937 (1 mg/kg, s.c.) suppresses pain responses elicited by i.p. injections of acetic acid[1].
URB937 in male rats (an oral dose 3 mg/kg, F = 36%) is absorbed at a moderate rate and displays a peak plasma concentration (Cmax) of 159.47 ng/ml, which was achieved one hour after administration. URB937 exhibits T1/2 of 60 min by an oral dose of 3 mg/kg[2].
URB937 produces a high degree of antinociception in female mice and rats in models of visceral and inflammatory pain. Moreover, the compound displayed a restricted access to placental and fetal tissues in pregnant mice and rats[3].
URB937 (1 mg/kg, every 2 days for 30 days) attenuates radiation-induced lung injury and increased endocannabinoid concentration in lung tissue[4].
| Animal Model: | Swiss Webster mice[1]. |
| Dosage: | 1 mg/kg. |
| Administration: | S.C. |
| Result: | Suppressesd pain responses elicited by i.p. injections of acetic acid. |
| Animal Model: | Adult Sprague Dawley male and female rats (250-300 g)[2]. |
| Dosage: | 0.3, 1, 3, 10 mg/kg (Pharmacokinetic Analysis). |
| Administration: | Single oral dose. |
| Result: | Inhibited liver FAAH activity with a median effective dose (ED50) of 0.9 mg/kg.
Inhibits FAAH in peripheral tissues and identify a possible biomarker for target engagement.
|
